Regional Dynamics and Prevalence of COVID-19 Variants in US Health and Human Services Regions
Speaker(s)
Hu L1, Zhang X1, Weimer I2, Yapici HO1, Shenoy A1, Lodaya K1, D'Souza F1
1Boston Strategic Partners, Inc., Boston, MA, USA, 2Boston Strategic Partners, Inc., Saint Paul, MN, USA
Presentation Documents
OBJECTIVES: The purpose of this research study is to identify the relative share of COVID-19 variants in Health and Human Services (HHS) regions in the United States, and to examine regional dynamics and prevalence of specific COVID-19 variants in the regions. The findings from this research will offer novel perspectives in analyzing regional distribution and trends of specific COVID-19 variants, which could be complementary to the current research on public health strategies.
METHODS: Utilizing data from the National COVID Cohort Collaborative (N3C) database, we monitored the progression of four prevalent COVID-19 variants (Delta, Omicron BA.5, Alpha, and XBB.1.5) across various U.S. HHS regions at three-month intervals. This approach has given way to a comprehensive analysis of regional trends and variant prevalence.
RESULTS: Our study found clear regional patterns of the distribution of COVID-19 variants of concern. The Delta variant initially surged in the Kansas City region, while the Omicron subvariant BA.5 exhibited a unique nationwide spread. The Alpha variant predominantly surfaced in the Southeast, and the XBB.1.5 variant showed a higher concentration in the Northeast. These findings provide a detailed map of variant distribution across the U.S., highlighting the diverse regional characteristics.
CONCLUSIONS: This research fills a crucial gap in understanding the regional dynamics of COVID-19 variant distribution. By providing detailed insights into the geographical prevalence of specific variants, our study offers valuable information for future targeted public health strategies and policies.
Code
EPH149
Topic
Epidemiology & Public Health
Topic Subcategory
Public Health
Disease
Infectious Disease (non-vaccine), No Additional Disease & Conditions/Specialized Treatment Areas